Select Medical Holdings Corporation宣布股东批准由 Robert A. Ortenzio、Martin F. Jackson和 WCAS领导的财团进行的收购-动脉网

Select Medical Holdings Corporation Announces Stockholder Approval of Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson, and WCAS

PR Newswire 等信源发布 2026-06-27 05:18



可切换为仅中文







MECHANICSBURG, Pa.

宾夕法尼亚州梅卡尼克斯堡

，

June 26, 2026

2026年6月26日

/PRNewswire/ -- Select Medical Holdings Corporation (NYSE:

/美通社/ -- Select Medical Holdings Corporation（纽约证券交易所：

SEM

扫描电子显微镜

) ('Select Medical,' 'we,' 'us,' or 'our') confirmed today that its previously announced Agreement and Plan of Merger (the 'Merger Agreement,' and the transaction contemplated thereby, the 'Merger') with an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F.

)（“Select Medical”、“我们”或“我们的”）今日确认，其此前宣布的与由Select Medical执行主席、联合创始人兼董事Robert A. Ortenzio以及Martin F.

Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe ('WCAS' and, together with Mr. Ortenzio and Mr. Jackson, the 'Consortium') was approved at a special meeting of Select Medical's stockholders (the 'Special Meeting') on June 26, 2026.

Select Medical 战略财务与运营高级执行副总裁 Jackson，以及 Welsh, Carson, Anderson & Stowe（“WCAS”，与 Ortenzio 先生和 Jackson 先生合称“财团”）于 2026 年 6 月 26 日在 Select Medical 股东特别会议（“特别会议”）上获得批准。

The closing of the Merger remains subject to the terms and conditions of the Merger Agreement, as described more in detail in the Definitive Proxy Statement on Schedule 14A (the 'Definitive Proxy Statement'), filed with the U.S. Securities and Exchange Commission (the 'SEC') on May 19, 2026. Subject to those terms and conditions, Select Medical expects that the closing of the Merger will occur mid-2026..

合并的完成仍须遵守《合并协议》的条款和条件，详见于2026年5月19日向美国证券交易委员会（“SEC”）提交的附表14A最终委托书声明（“最终委托书声明”）。在满足上述条款和条件的前提下，Select Medical预计合并将于2026年年中完成。

Approximately 82.54% of Select Medical's outstanding shares were voted at the Special Meeting, and the Merger was approved by over 79.88% of Select Medical's outstanding shares and over 76.64% of the outstanding shares held by stockholders unaffiliated with the Consortium. Select Medical will file the final voting results in a Current Report on Form 8-K with the SEC..

在特别会议上，Select Medical 约 82.54% 的已发行股份参与了投票，合并方案获得了 Select Medical 超过 79.88% 的已发行股份以及超过 76.64% 由非 Consortium 关联股东持有的已发行股份的批准。Select Medical 将向美国证券交易委员会（SEC）提交一份 8-K 表格的当前报告，以披露最终投票结果。

Advisors

顾问

J.P. Morgan and Wells Fargo are serving as joint lead arrangers and joint lead bookrunners in connection with the committed debt financing of the Consortium. Goldman Sachs is serving as the exclusive financial advisor, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel to the Special Committee of disinterested and independent directors of the Board of Directors of the Company.

摩根大通和富国银行担任与财团承诺债务融资相关的联合牵头安排行和联合牵头账簿管理人。高盛担任独家财务顾问，而Skadden, Arps, Slate, Meagher & Flom LLP则担任公司董事会中无利害关系且独立的董事组成的特别委员会的法律顾问。

Dechert LLP is serving as legal counsel to Select Medical. Wells Fargo and J.P. Morgan are serving as financial advisors, and Cravath, Swaine & Moore LLP is serving as legal counsel to the Consortium. Barclays is serving as financial advisor, and Ropes & Gray LLP is serving as legal counsel to WCAS.

德杰律师事务所（Dechert LLP）担任Select Medical的法律顾问。富国银行和摩根大通担任财务顾问，而科瓦顿·斯温摩尔律师事务所（Cravath, Swaine & Moore LLP）担任该财团的法律顾问。巴克莱银行担任财务顾问，而罗普斯与格雷律师事务所（Ropes & Gray LLP）担任WCAS的法律顾问。

Paul Hastings LLP is serving as legal counsel to the debt financing sources..

保罗·黑斯廷斯律师事务所正担任债务融资方的法律顾问。

About Select Medical

关于Select Medical

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States based on number of facilities. Select Medical's reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, and the outpatient rehabilitation segment.

Select Medical 是美国最大的危重病康复医院、康复医院和门诊康复诊所运营商之一，按设施数量计算。Select Medical 的报告分部包括危重病康复医院分部、康复医院分部和门诊康复分部。

As of March 31, 2026, Select Medical operated 103 critical illness recovery hospitals in 28 states, 41 rehabilitation hospitals in 15 states, and 1,912 outpatient rehabilitation clinics in 37 states and the District of Columbia. At March 31, 2026, Select Medical had operations in 38 states and the District of Columbia.

截至2026年3月31日，Select Medical在28个州运营着103家危重病康复医院，在15个州运营着41家康复医院，并在37个州及哥伦比亚特区运营着1,912家门诊康复诊所。截至2026年3月31日，Select Medical的业务覆盖38个州及哥伦比亚特区。

Information about Select Medical is available at .

有关 Select Medical 的信息可在 .

www.selectmedical.com

。

About WCAS

关于WCAS

WCAS is a leading U.S. private equity firm focused on two target industries: technology and healthcare. Since its founding in 1979, the firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives, and strategic acquisitions.

WCAS 是一家领先的美国私募股权公司，专注于科技和医疗健康两大目标行业。自1979年成立以来，该公司的战略一直是与卓越的管理团队合作，通过运营改善、增长举措和战略性收购相结合，为投资者创造价值。

The firm has raised and managed funds totaling over $33 billion of committed capital. For more information, please visit .

该公司已募集并管理承诺资本总额超过330亿美元的资金。欲了解更多信息，请访问。

www.wcas.com

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This release contains forward-looking statements. Forward-looking statements use words such as 'expect,' 'anticipate,' 'outlook,' 'intend,' 'plan,' 'confident,' 'believe,' 'will,' 'should,' 'would,' 'potential,' 'positioning,' 'proposed,' 'planned,' 'objective,' 'likely,' 'could,' 'may,' and words of similar meaning, as well as other words or expressions referencing future events, conditions or circumstances.

本次发布包含前瞻性陈述。前瞻性陈述使用诸如“预期”、“预计”、“展望”、“打算”、“计划”、“确信”、“相信”、“将”、“应该”、“将会”、“潜在”、“定位”、“提议”、“已计划”、“目标”、“可能”、“能够”、“也许”等具有类似含义的词语，以及引用未来事件、条件或情况的其他词语或表述。

Statements that describe or relate to Select Medical's plans, goals, intentions, strategies, financial outlook, are examples of forward-looking statements. Forward-looking statements are based on our current beliefs, expectations and assumptions, which may not prove to be accurate, and involve a number of known and unknown risks and uncertainties, many of which are out of Select Medical's control.

描述或涉及Select Medical的计划、目标、意图、战略和财务前景的陈述是前瞻性陈述的示例。前瞻性陈述基于我们当前的信念、预期和假设，这些可能并不准确，并且涉及许多已知和未知的风险与不确定性，其中许多超出了Select Medical的控制范围。

Forward-looking statements are not guarantees of future performance and you should not place undue reliance on Select Medical's forward-looking statements. Forward-looking statements involve significant known and unknown risks and uncertainties that may cause Select Medical's actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements.

前瞻性陈述并非对未来表现的保证，您不应过度依赖Select Medical的前瞻性陈述。前瞻性陈述涉及重大已知和未知的风险与不确定性，这些风险与不确定性可能导致Select Medical在未来期间的实际结果与前瞻性陈述中预测或设想的结果存在重大差异。

The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. There is no assurance that the proposed Merger will be consummated, and there are a number of risks and uncertainties that could cause actual outcomes and results to differ materially from the results contemplated by such forward-looking statements, including, without limitation: (1) the inability to consummate the proposed Merger within the anticipated time period, or at all, due to any reason, including the failure to obtain any required re.

此类陈述的纳入不应被视为表示此类计划、估计或预期将会实现。无法保证拟议的合并交易将完成，且存在多种风险和不确定性，可能导致实际结果与此类前瞻性陈述所预期的结果产生重大差异，包括但不限于：(1) 由于任何原因（包括未能获得任何所需的监管批准），导致拟议的合并交易未能在预期时间内完成，或根本无法完成。

Media inquiries:

媒体垂询：

Shelly Eckenroth

谢莉·埃肯罗斯

Senior Vice President, Chief Communications Marketing & Branding Officer

高级副总裁兼首席传播、营销与品牌官

717-920-4035

[email protected]

Investor inquiries:

投资者咨询：

Robert S. Kido